 |
|
Treatment of Alzheimer Disease
Vladimir Hachinski, MD, FRCPC, DScMed
London, Ontario
Arch Neurol. 1999;56:735.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
ANYTHING IS better than nothing in treating a relentlessly progressive disease. Gauthier argues convincingly that several drugs have shown definite, albeit modest amelioration of the symptoms of Alzheimer disease. Pryse-Phillips points out that many of these trials have been brief, typically 3 to 6 months, in a condition that usually spans 7 years after diagnosis, and that no drug halts the disease itself. Both contributions favor further and better trials.
While there always will be a place for symptomatic treatment, the most hopeful approach is to strike before the disease does. Converging evidence suggests that molecular dysfunction occurs decades before the clinical manifestations. The ability to identify high-risk groups by molecular markers may make it possible to begin prevention trials with drugs that interfere with brain amyloid interactions, agents with anti-inflammatory properties, and drugs aimed at other plausible mechanisms in brain degeneration. In the meantime, . . . [Full Text of this Article]
RELATED ARTICLES
Do We Have Drugs for Dementia?: No
William Pryse-Phillips
Arch Neurol. 1999;56(6):735-737.
EXTRACT
| FULL TEXT
Do We Have a Treatment for Alzheimer Disease?: Yes
Serge Gauthier
Arch Neurol. 1999;56(6):738-739.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials
Karlawish et al.
AJGP 2008;16:568-574.
ABSTRACT
| FULL TEXT
|
